Reason for request
Reassessment of the Actual Benefit of all medicines indicated in hormone replacement therapy for menopause at the request of the Committee, pursuant to Article R-163-21 of the French Social Security Code and Renewal of inclusion
Clinical Benefit
| Substantial |
The actual benefit of the proprietary medicinal products DIVINA and DUOVA 1 mg/2.5 mg, 1 mg/5 mg, 2 mg/5 mg in hormone replacement therapy (HRT) for symptoms of oestrogen deficiency in menopausal women remains substantial in patients for whom climacteric disorders are described as troublesome enough to impair their quality of life when these proprietary medicinal products are used as per the Committee's recommendations. |
Therapeutic use
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
DsMBrVZBmEzrGr78
